The multicentre, randomised, active-controlled AZALEA-TIMI 71 trial (NCT04755283) compared the bleeding profile of the factor XI inhibitor abelacimab with the DOAC rivaroxaban in patients with AF and a moderate-to-high risk of stroke. The participants (n=1,287) were randomised in a 1:1:1 fashion to receive 90 mg or 150 mg abelacimab, subcutaneously administered, once per month, or 20 mg rivaroxaban, orally administered, once daily. The primary endpoint was major or clinically relevant non-major (CRNM) bleeding. Dr Christian Ruff (Brigham and Women’s Hospital, MA, USA) presented the key findings.
“The trial was terminated early because the data monitoring committee reported that abelacimab yielded a larger than anticipated reduction in the primary endpoint compared with the active comparator,” announced Dr Ruff. At the time of termination of the trial, abelacimab displayed a factor XI inhibition >95% in both dose groups. Further, the occurrence of major or CRNM bleeding was significantly lower in the 90 mg group (HR 0.23; 95% CI 0.13–0.42; P<0.0001) and the 150 mg group (HR 0.33; 95% CI 0.19–0.55; P<0.0001) than in the rivaroxaban group.
No significant difference was observed in the risk of stroke or systemic embolism between the rivaroxaban group and either the 90 mg abelacimab group (HR 1.13; 95% CI 0.41–3.12; P=0.81) or the 150 mg group (HR 1.45; 95% CI 0.55–3.80; P=0.45). “However, the rates of these events were low and were only evaluated as exploratory endpoints,” commented Dr Ruff. Finally, there were no substantial differences between the safety profiles of the 2 agents.
- Ruff CT, et al. A multicentre randomised active-controlled study to evaluate the safety and tolerability of two blinded doses of abelacimab compared with open-label rivaroxaban in patients with atrial fibrillation. LB05, AHA Scientific Sessions 2023, 10–12 November, Philadelphia, USA.
Medical writing support was provided by Robert van den Heuvel.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« ORBITA-2 confirms PCI as alternative to anti-anginal drugs in stable angina Next Article
MINT: Liberal or restrictive transfusion strategy in MI with anaemia? »
« ORBITA-2 confirms PCI as alternative to anti-anginal drugs in stable angina Next Article
MINT: Liberal or restrictive transfusion strategy in MI with anaemia? »
Table of Contents: AHA 2023
Featured articles
Successful results for semaglutide in highly anticipated SELECT trial
Abelacimab substantially lowers bleeding risk compared with rivaroxaban
Online First
Pemafibrate reduces microvascular complications of PAD and T2D
Encouraging data for lepodisiran as Lp(a) lowering therapy
Nicotinamide riboside may improve walking function in PAD
Successful results for semaglutide in highly anticipated SELECT trial
Gene editing may change treatment landscape of hypercholesterolaemia
Biannual zilebesiran associated with substantial BP reductions
ARTESIA: How useful is anticoagulation in subclinical AF?
MINT: Liberal or restrictive transfusion strategy in MI with anaemia?
Abelacimab substantially lowers bleeding risk compared with rivaroxaban
ORBITA-2 confirms PCI as alternative to anti-anginal drugs in stable angina
Dapagliflozin improves cardiometabolic outcomes in MI
BP intervention saves lives of hypertensive pregnant women
Related Articles
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy